Surface Oncology (Surface Oncology) Interest Expense : $-5.77 Mil (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Surface Oncology Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Surface Oncology's interest expense for the three months ended in Jun. 2023 was $ -3.11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was $-5.77 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Surface Oncology's Operating Income for the three months ended in Jun. 2023 was $ -22.41 Mil. Surface Oncology's Interest Expense for the three months ended in Jun. 2023 was $ -3.11 Mil. Surface Oncology did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Surface Oncology Interest Expense Historical Data

The historical data trend for Surface Oncology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surface Oncology Interest Expense Chart

Surface Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-0.15

-2.86

-2.55

-3.15

Surface Oncology Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Interest Expense	Get a 7-Day Free Trial															-0.73	-0.83	-0.90	-0.93	-3.11

Surface Oncology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.77 Mil.

Surface Oncology (NAS:SURF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Surface Oncology's Interest Expense for the three months ended in Jun. 2023 was $-3.11 Mil. Its Operating Income for the three months ended in Jun. 2023 was $-22.41 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2023 was $0.00 Mil.

Surface Oncology's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Surface Oncology did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Surface Oncology (Surface Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139

Website

https://www.surfaceoncology.com

Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.

Executives

Chandra Adams	officer: Deputy GC	SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Alison Oneill	officer: Chief Medical Officer
Jessica Fees	officer: See Remarks	C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Robert W. Ross	officer: Chief Medical Officer	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Henry C. Rath	officer: Chief Business Officer	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139
Vito J. Palombella	officer: Chief Scientific Officer	780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Carsten Brunn	director	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Theresa Boni	officer: General Counsel	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Benjamin Hickey	director	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Liisa I Nogelo	officer: General Counsel	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Jeff Goater	director, officer: Chief Executive Officer	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David S. Grayzel	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Ix, L.p.	10 percent owner	46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118
Atlas Venture Associates Ix, Llc	10 percent owner	56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118